Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 386,722 shares, a growth of 121.5% from the October 15th total of 174,598 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average trading volume of 459,545 shares, the short-interest ratio is currently 0.8 days.
Institutional Trading of Pasithea Therapeutics
A hedge fund recently bought a new stake in Pasithea Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Pasithea Therapeutics Corp. (NASDAQ:KTTA – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 93,399 shares of the company’s stock, valued at approximately $69,000. Renaissance Technologies LLC owned 0.37% of Pasithea Therapeutics as of its most recent SEC filing. 23.92% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several analysts recently weighed in on KTTA shares. Zacks Research downgraded shares of Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Monday, September 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pasithea Therapeutics presently has a consensus rating of “Hold” and an average target price of $3.00.
Get Our Latest Stock Analysis on KTTA
Pasithea Therapeutics Price Performance
NASDAQ KTTA opened at $0.52 on Monday. Pasithea Therapeutics has a 12 month low of $0.28 and a 12 month high of $2.06. The firm has a market capitalization of $17.44 million, a PE ratio of -0.38 and a beta of 0.39. The company’s 50 day simple moving average is $0.48 and its 200 day simple moving average is $0.61.
Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Sell-side analysts anticipate that Pasithea Therapeutics will post -0.76 earnings per share for the current fiscal year.
Pasithea Therapeutics Company Profile
Pasithea Therapeutics is a clinical-stage biotechnology company developing therapies for serious diseases. Its current focus is PAS-004, a next-generation macrocyclic MEK inhibitor being studied for conditions associated with the RAS/MAPK signaling pathway, including neurofibromatosis type 1. The company’s research has shifted over time: Pasithea previously focused on treatments for neurological and psychiatric disorders. Its current development efforts are centered on PAS-004 and potential applications in diseases with limited treatment options.
Featured Stories
- Five stocks we like better than Pasithea Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
